Biologic Therapy for Osteoarthritis in Port St. Lucie, FL

CDC PLACES vs. JN: two files, not one brochure

CDC PLACES (2023, crude) estimates 13.1% of adults in Port St. Lucie have diagnosed diabetes — 1.1 points above the U.S. 12% figure. Census city-proper population is 204,851. If you are adding osteoarthritis biologic therapy, start with that epidemiology and with First Coast Service Options (JN) — not with a “near me” clinic listing. Hawk Medical ships nationwide; Joe Bradley’s own practice uses the same product classes.

Epidemiology is not a protocol

• Adult arthritis here is 27.9% (CDC PLACES 2023, crude). That is the joint-pain backdrop for PRP and orthobiologics — not a promise that every arthritic knee is a candidate. 14.5% of adults 18–64 here currently lack health insurance (CDC PLACES ACCESS2, 2023). Cash-pay PRP and Medicare CTPs cannot share one consent script. PRP is autologous and not a 361 allograft, but “patient prefers regenerative” is still not medical necessity in Florida.
• Medicare wound-care biologics in Florida are paid under First Coast Service Options (JN). CTP and skin-substitute LCDs are MAC-specific — a protocol that billed cleanly in another jurisdiction can stall here if documentation does not match JN coverage articles.
• A city under 250k usually means mixed payer mix: Medicare FFS under JN, Medicare Advantage, workers’ comp, and cash-pay sports medicine. One SKU list rarely serves all four without a utilization policy.

Uninsured mix and Medicare CTPs in the same building

JN reviewers still want serial wound measurements and conservative-care history before CTPs, whether diabetes in Port St. Lucie is 13.1% or not. PLACES is planning data. The LCD is the claim.

Before the first osteoarthritis biologic therapy shipment